EF Hutton Maintains Buy on Can Fite Biofarma, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Can Fite Biofarma (AMEX:CANF) and maintained a price target of $10.
September 24, 2024 | 2:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Can Fite Biofarma (AMEX:CANF) and maintained a price target of $10, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a $10 price target by EF Hutton suggests positive sentiment and confidence in Can Fite Biofarma's future performance. This could lead to increased investor interest and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100